In 1474 healthy Caucasoid men aged 45±65 y, insulin-like growth factor II (IGF2) Apal AA homozygotes showed a mean body weight 4 kg lower than Apal GG homozygotes (77.6610.9 kg vs 81.6611.5 kg, P50.003) with heterozygotes (GA) intermediate (80.1611.9 kg). The mean serum IGF-II concentration in 44 Apal AA individuals was signi®cantly higher than in 48 Apal GG individuals (683.36146.9 ng/ml vs 614.06124.0 ng/ml, P50.01). An INS Pstl polymorphism showed no association with weight and it was also found to be in minimal linkage disequilibrium with the IGF2 Apal site (coef®cient 0.016). The IGF2 Apal AA genotype is therefore associated with lower mean body weight but higher serum IGF-II concentrations than the GG genotype. Apal GG homozygotes incur a 1.67-fold risk of pathological Body Mass index (BMI) (b b 30 kg/m 2 ) compared with AA homozygotes.
Introduction
Obesity is associated with a wide range of physical disorders, some of which interact. Central (abdominal) obesity represents the main risk factor for both coronary disease and Type II diabetes, 1,2 with a steepening gradient of risk for Body Mass index (BMI) b 30 kg/m 2 . 3 In mice, but not humans, several single gene obesity disorders have been characterised, 4±6 however there is clear evidence from adoptee, individual, twin and family studies for a major genetic contribution to human weight variation and obesity. 7, 8 A locus for impaired glucose tolerance and adiposity near the insulin-like growth factor II (IGF2) and insulin gene cluster has been shown in the GotoKakizaki rat 9 . These genes are strong candidates both in the rat model 9 and on physiological grounds in human obesity. However we have investigated the relationship of an Apal polymorphism in the 3 H -noncoding region of IGF-II mRNA 10 with weight, BMI and IGF-II levels in 1474 healthy middle-aged men. Since an association has been found between the Class 3 allele insulin (INS) gene VNTR and waist/hip ratio in obese women 11 we also investigated the relationship of the INS Pstl polymorphism, 12 ( Figure 1 ) with weight and BMI.
Materials and methods

Study sample
The Northwick Park Heart Study II (NPHS II) sample consists in total of 3179 healthy Caucasoid men aged 45±65 y, recruited from nine general practices around the UK. 13 The investigation reported here involves a group of 1474 DNA samples from six of the UK general practices: Aston Clinton, Camberley, Carnoustie, Chester®eld, Halesworth and St Andrews.
DNA extraction
Genomic DNA was isolated from frozen whole blood by a salting-out method.
14 DNA samples were dried into the wells of Omniplates (Hybaid, Teddington, UK) prior to PCR. 15 
Oligonucleotides
Olignonucleotides were from Genosys, Cambridge, UK. The PCR primers used to amplify a 100 bp sequence encompassing the Apal site in the IGF2 PCR PCR setup was as described by Whittall et al.
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Thermal cycling conditions for the IGF2 gene PCR product were as in Tadokoro et al, 10 and for the insulin gene product were: 1 cycle, 95 C 5 min: 30 cycles, 95 C 1 min, 55 C 1 min, 72 C 2 min: 1 cycle, 72 C 5 min.
Restriction endonuclease analysis of PCR products
Apal and buffer were obtained from Boehringer (Mannheim, Germany). Pstl and buffer were obtained from New England Biolabs (Beverly, MA, USA). Digests were set up as described by Bolla et al, 17 with a ®nal concentration of 3.3 U/10 ml digestion volume, prior to analysis by microplate array diagonal gel electrophoresis (MADGE).
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Serum IGF-II radioimmunoassay
Forty-eight common and 44 rare Apal polymorphism homozygotes from the NPHS II sample were selected at random for quantitation of serum IGF-II. IGF-II was measured in sera previously stored at 745 C, by a coated-tube immunoradiometric assay (Diagnostic Systems Laboratories Inc., Webster, TX, USA), with an acid/ethanol extraction of the samples prior to analysis. The within assay coef®cients of variation (CV) were 4.3%, 7.2% and 4.3% at 63, 416 and 1585 ng/ml respectively, while between assay CV were 9.5%, 6.3% and 10.4% at 74, 427 and 1295 ng/ ml respectively. The analytical sensitivity of the assay was 15 ng/ml.
Statistical analysis
Chi-squared test of Hardy-Weinberg equilibrium was applied. Linkage disequilibrium between IGF2 Apal and INS Pstl sites was estimated as described by Chakravarti et al. 19 The distributions of IGF-II concentrations were log transformed to reduce skewness and kurtosis, prior to statistical analysis. Mean weight, height, BMI, cholesterol, triglyceride, and IGF-II levels for genotypes examined were compared by one-way analysis of variance.
Results
The associations between IGF2 Apal genotype (rare A allele frequency 0.28) and height, weight and BMI in 1474 individuals are shown in Table 1 . AA homozygotes had a mean body weight 4 kg lower than GG homozygotes (P 0.003), and the association with BMI (P 0.006) was due to the in¯uence on weight. Heterozygotes showed intermediate values for both weight and BMI. There was no association of genotype with height, serum cholesterol or triglyceride concentrations (Table 1) , nor with plasma creatinine concentrations (data not shown). Waist and waist/hip measurements were not available in the NPHS II sample.
A Pstl polymorphism is the 3 H untranslated region of the INS gene 11 (rare allele frequency 0.2) showed no association or trend with weight or BMI in a Serum IGF-II quantitation in 48 GG and 44 AA randomly selected homozygotes from the NPHS II sample showed a signi®cant difference; 614.0 AE 124.0 ng/ml in GG and 683.3 AE 146.9 ng/ml in AA homozygotes, (P 0.01).
Discussion
IGF2 Apal AA homozygotes have a mean body weight 4 kg lower than GG homozygotes, with heterozygotes showing intermediate values for both weight and BMI. The absence of an association with height is compatible with a known absence of an IGF-II effect on postnatal growth. The IGF2 Apal A allele was found to be associated with lower weight (AA average 4 kg lower than GG), BMI and higher IGF-II concentrations. This may re¯ect different channelling of metabolic substrate by IGF-II. In a dog model of the hypoglycaemic effects of insulin and IGF-I, an equivalent glucose clearance results in 68% glucose utilisation for IGF-I compared with 38% for insulin. 20 Given that IGF-II and IGF-I both act via the type I IGF receptor, higher IGF-II levels in Apal AA homozygotes could result in greater glucose utilisation in muscle, and hence less tendency to become obese. However the association between growth hormone, IGF-I and obesity is more complex than this 21 and IGF-II might act through other pathways. Furthermore, since most IGF is bound to binding proteins, total concentrations may not represent the amount of active hormone. Lastly, it is possible that the IGF2 Apal site imparts no direct in¯uence on IGF-II concentrations, but that the genotype is linked with weight in some way, with the serum IGF-II representing a remote downstream secondary effect. Nevertheless, the hypothesis we have proposed is the simplest one.
We calculate that GG homozygotes incur a 1.67-fold risk of pathological BMI compared with AA homozygotes, with heterozygotes intermediate.
Absence of genotype correlation with creatinine, absence of association with weight in 1619 young adults (data not shown) and absence of weight association with INS Pstl suggest a BMI effect independent of muscle mass and the INS gene which occurs only later in life. Allele-sharing and region-wide genotyping are underway, including the INS gene VNTR 11 and complete scans of the IGF2 gene and surrounding region, to identify all polymorphisms and build a full association map.
Conclusions
We have subsequently analysed the remainder of the NPHS sample, yielding data on 2605 individuals in total, of whom the 1474 described here were a subgroup. A total of 1379 GG individuals have mean weight 1.0 kg greater than that of 1040 GA individuals (P 0.03) and a 3.3 kg greater than that of 186 AA individuals (P 0.0002). Hence the effects described here are maintained in the extended sample, with even stronger statistical con®dence. GG vs AA P 0.006 for BMI; P 0.003 for weight. Absence of Hardy-Weinberg equilibrium between 1474 genotypes presented, is result of unavailability of complete data for 78 individuals in the total of 1552 genotypes, which were in equilibrium.
